Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBTH17 Cells May Serve as Biomarker in Metastatic Melanoma. By Morgan Bayer. September 28th 2024. TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Recent Approvals Signal a Bright Future for Myelodysplastic …
WEBDec 22, 2023 · Ivosidenib . In October 2023, ivosidenib (Tibsovo) was cleared by the FDA for the treatment of IDH1-mutated relapsed or refractory MDS, based on findings from the AG120-C-001 trial (NCT02074839).4 In the study, 18 adult patients with relapsed or refractory MDS with an IDH1 mutation received oral ivosidenib daily on a 28-day cycle. All responses in the trial were complete responses (CRs), and ...
Allegheny Health Network | Association Partnerships - Targeted …
WEBAssociation Partnerships. At Allegheny Health Network (AHN), compassion and innovation meet. We bring together groundbreaking procedures, advanced technology, and the latest research to create new models of care that provide exceptional health care. To refer a patient call 844-MD-REFER.
Nadofaragene Firadenovec Continues to Demonstrate Durable …
WEBJan 17, 2024 · Findings from the phase 3 trial rAd-IFN-CS-003 (NCT02773849) continued to show ongoing durable clinical activity for nadofaragene firadenovec-vncg (Adstiladrin) in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (± Ta/T1). 1 The 3-year data presented at the 2023 Society of Urologic Oncology ...
Managing Chemotherapy Toxicities for Improved Patient Outcomes
WEBMar 29, 2021 · In a large majority of patients, even when treating with chemotherapy that is highly emetogenic, nausea and vomiting can be prevented. Options include 5-HT3 receptor antagonists (such as ondansetron), NK-1 receptor antagonists (such as aprepitant), glucocorticoids (such as dexamethasone), and olanzapine, a …
Advancing T-Cell Redirecting Agents in Prostate Cancer
WEBDec 17, 2021 · 1. Sartor A. Advancing the Frontiers of T-Cell Redirecting Agents in Prostate Cancer. Presented at: 28th Annual Prostate Cancer Foundation Scientific Retreat; October 28-November 5, 2021; virtual. 2. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy.
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
WEBJan 25, 2024 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at the 2024 ASCO Genitourinary Cancers ...
FDA Acknowledges BLA of Zolbetuximab in HER2–, CLDN18.2
WEBMay 31, 2024 · The FDA has acknowledged the resubmitted biologics license application (BLA) for zolbetuximab (Vyloy) as a first-line treatment for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive. Zolbetuximab is a first-in-class investigational CLDN18.2-targeted monoclonal antibody.
ELEVATE Trial Shows Promise of Elacestrant Combinations in …
WEBAug 20, 2024 · Early results from the ELEVATE trial (NCT05563220), a phase 1b/2 study of elacestrant (Orserdu) given in combination with various targeted therapies, showed promise when used for the treatment of patients with estrogen receptor-positive (ER+)/HER2-negative (HER2–) metastatic breast cancer (mBC) who …